LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 134

Search options

  1. Book: PARTNER: a study of panitumumab plus chemotherapy for first line treatment of advanced head and neck cancer

    Wirth, Lori J.

    (Community oncology ; 5,10, Suppl. 14)

    2008  

    Title variant PARTNER: a study of panitumumab plus chemotherapy for first-line treatment of advanced head and neck cancer
    Author's details Lori J. Wirth
    Series title Community oncology ; 5,10, Suppl. 14
    Collection
    Language English
    Size 4 S.
    Publisher Elsevier Oncology
    Publishing place Huntington, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT015787373
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6521 -5,Suppl.14- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: New and emerging therapeutic options for thyroid carcinoma

    Shah, Jatin P. / Clayman, Gary L. / Wirth, Lori J.

    (Clinical advances in hematology & oncology : Clinical roundtable monograph ; volume 13, issue 4, supplement 4 (April 2015))

    2015  

    Author's details discussants Jatin P. Shah, MD; Gary L. Clayman, DMD, MD; Lori J. Wirth, MD
    Series title Clinical advances in hematology & oncology : Clinical roundtable monograph ; volume 13, issue 4, supplement 4 (April 2015)
    Clinical advances in hematology & oncology
    Clinical advances in hematology & oncology
    Collection Clinical advances in hematology & oncology
    Clinical advances in hematology & oncology
    Language English
    Size 18 Seiten, Diagramme
    Publisher Millennium Medical Publishing
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT019339088
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6505 -13,Suppl.4- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Still Perfecting Radioiodine in Thyroid Cancer, After All These Years.

    Wirth, Lori J

    The Journal of clinical endocrinology and metabolism

    2018  Volume 104, Issue 5, Page(s) 1655–1657

    MeSH term(s) Carcinoma, Papillary ; Humans ; Iodine Radioisotopes ; Proto-Oncogene Proteins B-raf ; Thyroid Neoplasms ; Vemurafenib
    Chemical Substances Iodine Radioisotopes ; Vemurafenib (207SMY3FQT) ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Language English
    Publishing date 2018-11-21
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/jc.2018-02437
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.134: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Checkpoint cluster: biomarkers of response.

    Pai, Sara I / Wirth, Lori J

    Emerging topics in life sciences

    2021  Volume 1, Issue 5, Page(s) 501–508

    Abstract: Current clinical knowledge surrounding one of the most promising immune checkpoint pathways, namely programmed cell death-1 (PD-1) and its ligands PD-L1 and PD-L2, is reviewed in the context of head and neck squamous cell carcinoma. The results of two ... ...

    Abstract Current clinical knowledge surrounding one of the most promising immune checkpoint pathways, namely programmed cell death-1 (PD-1) and its ligands PD-L1 and PD-L2, is reviewed in the context of head and neck squamous cell carcinoma. The results of two phase III clinical trials (KEYNOTE 040 and CheckMate 141) are critically examined. The utility of predictive biomarkers of response to immune checkpoint blockade, such as PD-L1/PD-L2 protein expression, interferon-gamma gene expression signatures, and mutational and neoantigen load, is discussed. Finally, we project future directions in the immuno-oncology field by discussing other promising predictive biomarkers as well as areas where the next advances are likely to take place, such as in the implementation of immune checkpoint inhibitors earlier in the course of cancer treatment and/or in combination therapies.
    Language English
    Publishing date 2021-01-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 2882721-1
    ISSN 2397-8554 ; 2397-8554 ; 2397-8562
    ISSN (online) 2397-8554
    ISSN 2397-8554 ; 2397-8562
    DOI 10.1042/ETLS20170077
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma.

    Wirth, Lori J

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2016  Volume 34, Issue 12, Page(s) 1289–1291

    MeSH term(s) Carcinoma, Squamous Cell ; Cetuximab ; Head and Neck Neoplasms ; Human papillomavirus 16 ; Humans ; Oropharyngeal Neoplasms ; Papillomaviridae ; Papillomavirus Infections
    Chemical Substances Cetuximab (PQX0D8J21J)
    Language English
    Publishing date 2016-04-20
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2015.65.1414
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.

    Wirth, Lori J

    Clinical advances in hematology ; & ; oncology : H ; & ; O

    2015  Volume 13, Issue 4 Suppl 4, Page(s) 9–16

    Language English
    Publishing date 2015-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.

    Gianoukakis, Andrew G / Choe, Jennifer H / Bowles, Daniel W / Brose, Marcia S / Wirth, Lori J / Owonikoko, Taofeek / Babajanyan, Svetlana / Worden, Francis P

    European thyroid journal

    2024  Volume 13, Issue 1

    Abstract: Background: The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear. Thus, we evaluated the real-world practice patterns and outcomes in ... ...

    Abstract Background: The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear. Thus, we evaluated the real-world practice patterns and outcomes in asymptomatic patients with progressive RAI-R DTC (≥1 lesion ≥1 cm in diameter) in the USA (US population) and outside the USA (non-US population).
    Methods: In this prospective, non-interventional, open-label study, eligible patients were chosen by treating physicians to receive MKI therapy (cohort 1) or undergo active surveillance (cohort 2) at study entry. Cohort 2 patients were allowed to transition to MKI therapy later. The primary endpoint was time to symptomatic progression (TTSP) from study entry. Data were compared descriptively. When endpoints were inestimable, 36-month rates were calculated.
    Results: Of the 647 patients, 478 underwent active surveillance (cohort 2) and 169 received MKI treatment (cohort 1). Patients underwent surveillance at a higher rate in the US (92.6%) vs the non-US (66.9%) populations. Half of US and non-US patients who qualified for MKI treatment had initial American Thyroid Association (ATA) low-to-intermediate-risk disease. In cohort 2, the 36-month TTSP rates from study entry were 65.6% and 66.5% in the US and non-US populations, respectively. Cohort 2 patients treated later demonstrated 36-month TTSP rates of 30.8% and 55.8% in the US and non-US populations, respectively.
    Conclusions: Active surveillance is a viable option for asymptomatic patients with progressive RAI-R DTC. However, early intervention with MKI therapy may be more suitable for others. Further research is needed to identify patients who are optimal for active surveillance.
    Registration: NCT02303444.
    MeSH term(s) Humans ; Thyroid Neoplasms/drug therapy ; Treatment Outcome ; Iodine Radioisotopes/therapeutic use ; Prospective Studies ; Adenocarcinoma/chemically induced
    Chemical Substances Iodine Radioisotopes
    Language English
    Publishing date 2024-01-24
    Publishing country England
    Document type Journal Article
    ZDB-ID 2659767-6
    ISSN 2235-0802 ; 2235-0640
    ISSN (online) 2235-0802
    ISSN 2235-0640
    DOI 10.1530/ETJ-23-0039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.

    Wirth, Lori J

    Clinical advances in hematology & oncology : H&O

    2015  Volume 13, Issue 4 Suppl 4, Page(s) 9–16

    MeSH term(s) Antineoplastic Agents/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Humans ; Molecular Targeted Therapy/methods ; Neoplasm Recurrence, Local/drug therapy ; Niacinamide/analogs & derivatives ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/pathology
    Chemical Substances Antineoplastic Agents ; Phenylurea Compounds ; Niacinamide (25X51I8RD4) ; sorafenib (9ZOQ3TZI87)
    Language English
    Publishing date 2015-10-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

    Deschler-Baier, Barbara / Konda, Bhavana / Massarelli, Erminia / Hu, Mimi I / Wirth, Lori J / Xu, Xiaojian / Wright, Jennifer / Clifton-Bligh, Roderick J

    The Journal of clinical endocrinology and metabolism

    2024  

    Abstract: Introduction: Activating RET alterations have been reported in a variety of solid tumors, including pheochromocytoma where they occur both sporadically and as part of familial multiple endocrine neoplasia type 2 (MEN2) syndromes. Selpercatinib is a ... ...

    Abstract Introduction: Activating RET alterations have been reported in a variety of solid tumors, including pheochromocytoma where they occur both sporadically and as part of familial multiple endocrine neoplasia type 2 (MEN2) syndromes. Selpercatinib is a first-in-class, highly selective, and potent small molecule RET kinase inhibitor that has demonstrated marked and durable anti-tumor activity in diverse RET-activated solid tumors in the LIBRETTO-001 study (NCT03157128).
    Methods: We describe the first six pheochromocytoma cases treated with selpercatinib in the LIBRETTO-001 study.
    Results: Of the six patients (one sporadic and five reported as part of MEN2 syndromes) in this case report, four had a partial response/complete response and two had stable disease per independent review committee. Treatment duration ranged from 9.2 months to more than 56.4 months. The safety profile of treatment was consistent with selpercatinib in other indications.
    Conclusion: These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.
    Language English
    Publishing date 2024-04-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgae283
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.134: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Medullary Thyroid Cancer: Updates and Challenges.

    Gild, Matti L / Clifton-Bligh, Roderick J / Wirth, Lori J / Robinson, Bruce G

    Endocrine reviews

    2023  Volume 44, Issue 5, Page(s) 934–946

    Abstract: A personalized approach to the management of medullary thyroid cancer (MTC) presents several challenges; however, in the past decade significant progress has been made in both diagnostic and treatment modalities. Germline rearranged in transfection (RET) ...

    Abstract A personalized approach to the management of medullary thyroid cancer (MTC) presents several challenges; however, in the past decade significant progress has been made in both diagnostic and treatment modalities. Germline rearranged in transfection (RET) testing in multiple endocrine neoplasia 2 and 3, and somatic RET testing in sporadic MTC have revolutionized the treatment options available to patients. Positron emission tomography imaging with novel radioligands has improved characterization of disease and a new international grading system can predict prognosis. Systemic therapy for persistent and metastatic disease has evolved significantly with targeted kinase therapy especially for those harboring germline or somatic RET variants. Selpercatinib and pralsetinib are highly selective RET kinase inhibitors that have shown improved progression-free survival with better tolerability than outcomes seen in earlier multikinase inhibitor studies. Here we discuss changes in paradigms for MTC patients: from determining RET alteration status upfront to novel techniques for the evaluation of this heterogenous disease. Successes and challenges with kinase inhibitor use will illustrate how managing this rare malignancy continues to evolve.
    MeSH term(s) Humans ; Carcinoma, Medullary/pathology ; Proto-Oncogene Proteins c-ret/genetics ; Carcinoma, Neuroendocrine/diagnosis ; Carcinoma, Neuroendocrine/genetics ; Carcinoma, Neuroendocrine/therapy ; Thyroid Neoplasms/diagnosis ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/genetics
    Chemical Substances Proto-Oncogene Proteins c-ret (EC 2.7.10.1)
    Language English
    Publishing date 2023-05-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603096-8
    ISSN 1945-7189 ; 0163-769X
    ISSN (online) 1945-7189
    ISSN 0163-769X
    DOI 10.1210/endrev/bnad013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1562: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top